“An examination of Celgene’s aggressive promotion of Revlimid and its predecessor, Thalomid, while Mr.It’s time he pays for what he did by helping those he made a fortune ripping off.” Really? Are you proud of jacking up the price of your cancer meds, putting patients at risk, and settling a Medicare fraud case for $280 million? Cancer patients have suffered enough at the hands of Bob Hugin. “Bob Hugin says he’s proud of all he did at Celgene. “Today’s New York Times report lays out in clear, black and white how Bob Hugin put profits over patients and gamed the system to get rich,” said Menendez for Senate Communications Director Steve Sandberg. The investigative report published today in the New York Times looks into Bob Hugin’s reign as CEO of pharma giant Celgene, specifically his business practices that ran afoul of federal law and are the focus of mounting lawsuits against the company, including a Medicare whistle-blower fraud case Hugin settled last year for $280 million.

New Brunswick, NJ – Pointing to an investigative report by the New York Times, Senator Menendez’s campaign today called on greedy drug company CEO Bob Hugin to use some of the blood money he made ripping off cancer patients to help patients pay the high cost of prescription drugs and support cancer research. Time for Hugin to pay for sins at Celgene NEW YORK TIMES INVESTIGATION: Hugin & Celgene ‘By Far the Worst Offender’

Robert hugin celgene